Halo snaps up Abbott facility; saves 80 New Jersey jobs

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology

Halo Pharmaceuticals hopes that its acquisition of Abbott Laboratories’ 200,000 sq ft formulation, manufacturing and warehousing facility in Whippany, New Jersey will help it blossom into a CMO and development organisation.

Through the deal Halo gains aseptic filling capacity for solid, liquid and topical dosage forms, as well as several packaging lines and considerable laboratory space that it plans to use for its preclinical and clinical development offering.

The site also holds US Drug Enforcement Administration (DEA) clearance for the manufacture of controlled drug substances and active pharmaceutical ingredients (APIs), which should serve the new firm well given the growing market for high-potency APIs.

The sale, financial terms of which are not being released, was first mooted in October last year as part of Abbott’s wide ranging consolidation strategy that has seen it focus on core products like Humira (adalimumab).

Halo president Douglas Kollmorgen said that the firm will retain 80 of the 134 staff previously employed at the site, explaining that the skilled and experienced workforce was a key motivation for making the acquisition in the first place.

This aspect of the purchase in particular is welcome news for New Jersey which saw companies like Par, Johnson & Johnson and Roche cut staffing levels at facilities in the region in 2008.

This Whippany facility’s track record was also emphasised by Halo’s vice president of quality, John Garvey, who commended Abbott for fostering a culture of regulatory compliance and diligence.

These important foundational elements will enable the creation of a systems approach to quality with a focus on science-based, product-driven control frameworks that meet or exceed current [US Food and Drug Administration] FDA regulatory requirements,”​ added Garvey.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars